StockData

Precision BioSciences vs Intellia Therapeutics

DTIL and NTLA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How DTIL and NTLA compare

Intellia Therapeutics is the larger company, worth 7.0 times as much as Precision BioSciences ($1.4B against $195M).

Precision BioSciences grew revenue faster over the last twelve months (3473% versus 12.6% for Intellia Therapeutics).

Precision BioSciences keeps more of each dollar of sales as profit, with a net margin of −117% compared with −672% at Intellia Therapeutics.

Intellia Therapeutics scores higher on the StockData Score (8 against 4 for Precision BioSciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricDTILNTLA
Size and price
Market cap$195M$1.4B
Share price$7.05$9.78
Change, 1 year19.9%12.4%
Change, 5 years−97.4%−91.4%
Beta (5Y)−0.531.65
Employees68377
StockData Score
Total score48 (better)
Valuation score01 (better)
Growth score2 (better)1
Performance score11
Health score15 (better)
Dividend score00
Valuation
P/S4.3× (better)23.0×
P/B4.3×1.9× (better)
FCF yield−26.7%−25.4% (better)
Fair value$4.46$9.13
Margin of safety−58.2%−7.2% (better)
Growth
Revenue growth (TTM)3473% (better)12.6%
Revenue growth, 5Y average7.1% (better)3.1%
Profitability
Operating margin−80.8% (better)−712%
Net margin−117% (better)−672%
FCF margin−115% (better)−586%
Return on equity−133% (better)−6425%
Financial health
Debt / equity–0.00
Interest coverage−27.6×–
Current ratio12.82 (better)6.65
Altman Z-score−4.780.86 (better)
Piotroski F-score23 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions64.0%103%
Held by insiders3.0%2.0%
Insider net buying, 12 months−$396K (better)−$869K
Short interest, % of float7.8%32.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.